shRNA-mediated knock-down (KD) of SNAI1 in human AML cell lines was found to lead to enhanced morphological differentiation as assayed by May–Grunwald–Giemsa staining analysis and increased mature CD11B (Integrin αM protein) myeloid marker expression in flow cytometry analysis [163], similar to the effects associated with ZEB2 KD [142]. Here, SNAI1 is linked to acute myeloid leukemia.